DOI QR코드

DOI QR Code

Analysis of Radiofrequency Ablation of Small Renal Tumors in Patients at High Anesthetic and Surgical Risk: Urologist Experience with Follow-up Results in the Initial Six Months

  • Yuksel, Mehmet Bilgehan (Department of Urology, Faculty of Medicine, Celal Bayar University) ;
  • Karakose, Ayhan (Department of Urology, School of Medicine, Izmir University) ;
  • Gumus, Bilal (Department of Urology, Faculty of Medicine, Celal Bayar University) ;
  • Tarhan, Serdar (Department of Radiology, Faculty of Medicine, Celal Bayar University) ;
  • Atesci, Yusuf Ziya (Department of Urology, School of Medicine, Izmir University) ;
  • Akan, Zafer (Department of Biophysics, Faculty of Medicine, Celal Bayar University)
  • 발행 : 2013.11.30

초록

Background: To evaluate the results of various types of radiofrequency ablation (RFA) treatment of renal tumors in patients with excessive anesthetic and surgical risk. Materials and Methods: Data for RFA performed in in high risk patients were retrospectively evaluated. Other RFA applications in patients with no anesthetic and/or surgical risk were excluded. RFA was by ultrasound or CT guided percutaneous (USG/CT-PRFA) and retroperitoneally or transperitoneally laparoscopic (R/T-LRFA) techniques under general or local anethesia. Follow-up data of enhanced CT or MRI after 1, 3 and 6 months were analysed for twelve RFA applications. Results: The RFA applications included 4 (40%) left-sided, 5 (50%) right-sided and 1 (10%) bilaterally RFA (simultaneously 1 right and 2 left). The localizations of tumors were 2 (16.6%) upper, 5 (41.6%) mid and 5 (41.6%) lower pole. The RFA applications included 9 (75%) USG-PRFA, 1 (8.3%) CT-PRFA, 1 (8.3%) T-LRFA and 1 (8.3%) R-LRFA. The mean age was $65.3{\pm}8.5$ (52-76) years. The mean tumor size was $29.6{\pm}6.08$ (15-40) mm. No complications related to the RFA were encountered in any of the cases. Failure (residual tumour) was determined in 8.3% (1/12) of USG-RFA application. The success rate was thus 91.7% (11/12). Other 1st, 3rd and 6th months follow-up data revealed no residua and recurrence. Conclusions: RFA application appears to be safe as a less invasive and effective treatment modality in selected cases of small renal tumors in individuals with excessive anesthetic and also surgical risk.

키워드

참고문헌

  1. Altunrende F, Autorino R, Hillyer S, et al (2011). Image guided percutaneous probe ablation for renal tumors in 65 solitary kidneys, functional and oncological outcomes. J Urol, 186, 35-41. https://doi.org/10.1016/j.juro.2011.03.024
  2. Arima K, Yamakado K, Kinbara H, et al (2007). Percutaneous radiofrequency ablation with transarterial embolization is useful for treatment of stage 1 renal cell carcinoma with surgical risk, results at 2-year mean follow up. Int J Urol, 14, 585-90. https://doi.org/10.1111/j.1442-2042.2007.01740.x
  3. Aron M, Gill IS (2005). Renal tumor ablation. Curr Opin Urol, 15, 298-305. https://doi.org/10.1097/01.mou.0000177684.93531.85
  4. Atwell TD, Carter RE, Schmit GD, et al (2012). Complications following 573 percutaneous renal RF and cryoablation procedures. J Vasc Interv Radiol, 23, 48-54. https://doi.org/10.1016/j.jvir.2011.09.008
  5. Best SL, Park SK, Yaacoub RF, et al (2012). Long term outcomes of renal tumors RFA stratified by tumor diameter, size matters. J Urol, 187, 1183-9. https://doi.org/10.1016/j.juro.2011.11.096
  6. Breau RH, Crispen PL, Jenkins SM, et al (2011). Treatment of patients with small renal masses, a survey of the American urological association. J Urol, 185, 407-13. https://doi.org/10.1016/j.juro.2010.09.092
  7. Breen DJ, Rutherford EE, Stedman B, et al (2007). Management of renal tumors by image- guided radiofrequency ablation, experience in 105 tumors. Cardiovasc Intervent Radiol, 30, 936-42. https://doi.org/10.1007/s00270-007-9090-x
  8. Campbell SC, Novick AC, Bukowski RM (2007). Renal tumors. In, Campbell MF, Wein AJ, Kavoussi LR, eds. Campbell-Walsh Urology. 9th ed. Philadelphia, PA, Saunders Elsevier, 1567-637.
  9. Campbell SC, Novick AC, Belldegrun A, et al (2009). Guideline for management of the clinical T1 renal mass. J Urol, 182, 1271-9. https://doi.org/10.1016/j.juro.2009.07.004
  10. Chen DY, Uzzo RG (2009). Optimal management of localized renal cell carcinoma, surgery, ablation, or active surveillance. J Natl Compr Canc Netw, 7, 635-42. https://doi.org/10.6004/jnccn.2009.0044
  11. Del Cura JL, Zabala R, Iriarte JI, et al (2010). Treatment of renal tumors by percutaneous ultrasound-guided radiofrequency ablation using a multitined electrode, effectiveness and complications. Eur Urol, 57, 459-65. https://doi.org/10.1016/j.eururo.2009.11.025
  12. Ferakis N, Bouropoulos C, Granitsas T, et al (2010). Long-term results after computed tomography-guided percutaneous radiofrequency ablation for small renal tumors. J Endourol, 24, 1909-13. https://doi.org/10.1089/end.2009.0639
  13. Fergany AF, Hafez KS, Novick AC (2000). Long-term results of nephron sparing surgery for localized renal cell carcinoma, 10-year followup. J Urol, 163, 442-5. https://doi.org/10.1016/S0022-5347(05)67896-2
  14. Gervais DA, McGovern FJ, Arellano RS, et al (2005). Radiofrequency ablation of renal cell carcinoma, part 1, Indications, results, and role in patient management over a 6-year period and ablation of 100 tumors. AJR Am J Roentgenol, 185, 64-71. https://doi.org/10.2214/ajr.185.1.01850064
  15. Gill IS, Kavoussi LR, Lane BR, et al (2007). Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol, 178, 41-6. https://doi.org/10.1016/j.juro.2007.03.038
  16. Hacker A, Vallo S, Weiss C, et al (2006). Technical characterization of a new bipolar and multipolar radiofrequency device for minimally invasive treatment of renal tumours. BJU Int, 97, 822-8. https://doi.org/10.1111/j.1464-410X.2006.06038.x
  17. Huang WC, Levey AS, Serio AM, et al (2006). Chronic kidney disease after nephrectomy in patients with renal cortical tumours, a retrospective cohort study. Lancet Oncol, 7, 735-40. https://doi.org/10.1016/S1470-2045(06)70803-8
  18. Iannuccilli JD, Dupuy DE, Mayo-Smith WW (2012). Solid renal masses, effectiveness and safety of image-guided percutaneous radiofrequency ablation. Abdom Imaging, 37, 647-58. https://doi.org/10.1007/s00261-011-9807-9
  19. Ji C, Li X, Zhang S, et al (2011). Laparoscopic radiofrequency ablation of renal tumors, 32 months mean follow-up results of 106 patients. Urology, 77, 798-802. https://doi.org/10.1016/j.urology.2010.10.014
  20. Karam JA, Ahrar K, Vikram R, et al (2013). Radiofrequency ablation of renal tumours with clinical, radiographical and pathological results. BJU Int, 111, 997-1005. https://doi.org/10.1111/j.1464-410X.2012.11608.x
  21. Kwan KG, Matsumoto ED (2007). Radiofrequency ablation and cryoablation of renal tumours. Curr Oncol,14, 34-8. https://doi.org/10.3747/co.2007.113
  22. Kim SD, Yoon SG, Sung GT (2012). Radiofrequency ablation of renal tumors, four-year follow-up results in 47 patients. Korean J Radiol, 13, 625-33. https://doi.org/10.3348/kjr.2012.13.5.625
  23. Karam JA, Ahrar K, Vikram R, et al (2013). Radiofrequency ablation of renal tumours with clinical, radiographical and pathological results. BJU Int, 111, 997-1005. https://doi.org/10.1111/j.1464-410X.2012.11608.x
  24. Laguna M, Zondervan PJ, de la Rosette J (2012). Focal therapy in the management of small renal masses. Curr Opin Urol, 22, 372-8. https://doi.org/10.1097/MOU.0b013e328355a9a7
  25. Lucas SM, Stern JM, Adibi M, et al (2008). Renal function outcomes in patients treated for renal masses smaller than 4 cm by ablative and extirpative techniques. J Urol, 179, 75-9.
  26. Ljungberg B, Cowan NC, Hanbury DC, et al (2010). EAU guidelines on renal cell carcinoma, the 2010 update. Eur Urol, 58, 398-406. https://doi.org/10.1016/j.eururo.2010.06.032
  27. Matsumoto ED, Johnson DB, Ogan K, et al (2005). Short-term efficacy of temperature-(2012). based radiofrequency ablation of small renal tumors. Urology, 65, 877-81. https://doi.org/10.1016/j.urology.2004.12.011
  28. Mylona S, Kokkinaki A, Pomoni M, et al (2009). Percutaneous radiofrequency ablation of renal cell carcinomas in patients with solitary kidney, 6 years experience. Eur J Radiol, 69, 351-6. https://doi.org/10.1016/j.ejrad.2007.10.004
  29. Okhunov Z, Roy O, Duty B, et al (2012). Clinical evaluation of a novel bipolar radiofrequency ablation system for renal masses. BJU Int, 110, 688-91. https://doi.org/10.1111/j.1464-410X.2012.10940.x
  30. Park S, Anderson JK, Matsumoto ED, et al (2006). Radiofrequency ablation of renal tumors, intermediate-term results. J Endourol, 20, 569-73. https://doi.org/10.1089/end.2006.20.569
  31. Park BK, Kim CK, (2009). Complications of image-guided radiofrequency ablation of renal cell carcinoma, causes, imaging features, and prevention methods. Eur Radiol, 19, 2180-90. https://doi.org/10.1007/s00330-009-1399-1
  32. Pasticier G, Timsit MO, Badet L, et al (2006). Nephron-sparing surgery for renal cell carcinoma, detailed analysis of complications over a 15-year period. Eur Urol, 49, 485-90. https://doi.org/10.1016/j.eururo.2005.12.049
  33. Salas N, Ramanathan R, Dummett S, et al (2010). Results of radiofrequency kidney tumor ablation, renal function preservation and oncologic efficacy. World J Urol, 28, 583-91. https://doi.org/10.1007/s00345-010-0562-2
  34. Wingo MS, Leveillee RJ (2008). Central and deep renal tumors can be effectively ablated, radiofrequency ablation outcomes with fiberoptic peripheral temperature monitoring. J Endourol, 22, 1261-7. https://doi.org/10.1089/end.2008.0135
  35. Tracy CR, Raman JD, Donnally C, et al (2010). Durable oncologic outcomes after radiofrequency ablation, experience from treating 243 small renal masses over 7,5 years. Cancer, 116, 3135-42. https://doi.org/10.1002/cncr.25002
  36. Zagoria RJ, Traver MA, Werle DM, et al (2007). Oncologic efficacy of CT-guided percutaneous radiofrequency ablation of renal cell carcinomas. AJR Am J Roentgenol, 189, 429-36. https://doi.org/10.2214/AJR.07.2258
  37. Zlotta AR, Wildschutz T, Raviv G, et al (1997). Radiofrequency interstitial tumor ablation (RITA) is a possible new modality for treatment of renal cancer, ex vivo and in vivo experience. J Endourol, 11, 251-8. https://doi.org/10.1089/end.1997.11.251